Use of bioclinical markers for the assessment and treatment of children with pervasive developmental disorders.
The method presented is based on the 3-dimensional bioclinical examination of autistic children. The covariations of behavior ratings, electrophysiological (cortical evoked potentials) and biochemical (urinary monoamine metabolites) measurements are analyzed. The systematic application of these markers provides precise information for a more rational application of therapeutics. It could help to better understand the underlying mechanisms of autism.
Adrien
J L
JL
Départment de Psychopathologie et de Neurophysiologie du Développment, INSERM U316, CHU Bretonneau, Tours, France.
Barthélémy
C
C
Lelord
G
G
Muh
J P
JP
D001143:Arousal / Q000502:physiology; D001321:Autistic Disorder / Q000175:diagnosis* / Q000628:therapy; D002395:Catecholamines / Q000652:urine; D002540:Cerebral Cortex / Q000503:physiopathology; D002648:Child; D004569:Electroencephalography; D005500:Follow-Up Studies; D006801:Humans; D011569:Psychiatric Status Rating Scales
D002395:Catecholamines